TABLE 3.
Treatment change | n | % |
---|---|---|
Switched from CTx to treatment without chemotherapy | ||
CTx + octreotide → octreotide | 6 | 6.8 |
CTx + octreotide → octreotide + surgery | 1 | 1.1 |
CTx + octreotide → watch-and-wait | 1 | 1.1 |
CTx + octreotide + other → octreotide | 2 | 2.3 |
CTx + octreotide + PRRT → octreotide | 1 | 1.1 |
CTx + octreotide + PRRT → octreotide + surgery | 1 | 1.1 |
CTx + octreotide + PRRT + other → surgery | 1 | 1.1 |
CTx + octreotide + PRRT + other → octreotide + surgery | 2 | 2.3 |
CTx + octreotide + surgery → octreotide | 1 | 1.1 |
CTx + octreotide + surgery → octreotide + surgery | 1 | 1.1 |
CTx + octreotide + surgery + PRRT → octreotide + surgery + other | 1 | 1.1 |
CTx + octreotide + surgery + PRRT + other → octreotide | 1 | 1.1 |
CTx + RTx + surgery → PRRT | 1 | 1.1 |
Total | 20 | 22.7 |
Switched to a chemotherapy-including treatment plan | ||
Octreotide → CTx + octreotide | 1 | 1.1 |
Watch-and-wait → CTx + octreotide + surgery | 1 | 1.1 |
Watch-and-wait → CTx + octreotide + surgery + other | 1 | 1.1 |
Total | 3 | 3.4 |
Watch-and-wait changed to other treatment strategies | ||
Watch-and-wait → octreotide + surgery | 2 | 2.3 |
Watch-and-Wait → CTx + octreotide + surgery | 1 | 1.1 |
Watch-and-wait → CTx + octreotide + surgery + other | 1 | 1.1 |
Watch-and-wait + octreotide → octreotide | 1 | 1.1 |
Watch-and-wait + octreotide → octreotide + surgery | 1 | 1.1 |
Total | 6 | 6.8 |
Initial treatment strategy switched to watch-and-wait | ||
Surgery → watch-and-wait | 1 | 1.1 |
Octreotide → watch-and-wait | 2 | 2.3 |
Octreotide + surgery + other → watch-and-wait | 1 | 1.1 |
CTx + octreotide → watch-and-wait | 1 | 1.1 |
Total | 5 | 5.7 |
Surgery switched to surgery + octreotide or watch-and-wait | ||
Surgery → octreotide + surgery | 2 | 2.3% |
Surgery → watch-and-wait | 1 | 1.1% |
Total | 3 | 3.4% |
Switched from a multimodality approach to surgery alone | ||
CTx + octreotide + PRRT + other → surgery | 1 | 1.1% |
Total | 1 | 1.1% |
CTx = chemotherapy; RTx = radiotherapy.